New Zealand regulator approves MDMA for severe PTSD treatment

Two psychiatrists in New Zealand received approval on Friday from Medsafe, the nation’s pharmaceutical regulator, to prescribe pharmaceutical‑grade MDMA to patients suffering from severe post‑traumatic stress disorder (PTSD). The decision makes New Zealand the second country globally to authorize the party drug for therapeutic use, following Australia’s 2023 approval that also extended to treatment‑resistant depression. The New Zealand approval is limited to a controlled clinical setting, where MDMA‑assisted psychotherapy will be administered under strict medical supervision to individuals who have not responded to conventional treatments.

The regulatory move reflects a growing international interest in psychedelic‑based therapies as potential alternatives for mental‑health conditions that remain difficult to treat. Health officials emphasized that the approval does not constitute a general market release; instead, it authorizes a narrowly defined protocol involving qualified psychiatrists and rigorous safety monitoring. As the first patients begin treatment, the outcome will inform future policy considerations and could shape the broader adoption of psychedelic medicines in the region.